药动学-药效学模型在新药评价中的应用

被引：25

作者：

庄露凝 ^{[1
,2
,3
]}

谷元 ^{[1
,2
]}

刘昌孝 ^{[2
]}

机构：

[1] 天津大学化工学院

[2] 天津药物研究院释药技术与药代动力学国家重点实验室

[3] 佛罗里达大学药学院

来源：

药物评价研究 | 2011年 / 34卷 / 03期

关键词：

药动学; 药效学; PK/PD模型; 药物评价;

D O I：

暂无

中图分类号：

R969.1 [药物代谢动力学];

学科分类号：

100710 [药物代谢动力学];

摘要：

新药评价已经成为新药研发中最关键的阶段,也是安全合理用药所面临的重大课题。近年来,药动学-药效学(PK/PD)模型受到了越来越广泛的关注,这一模型是将PK和PD两个相互关联的动力学过程有机地结合起来,同时探讨机体对药物的作用及药物对机体的作用,为更全面和准确地了解药物的效应随剂量(或浓度)及时间而变化的规律,从而为临床用药的安全性和有效性提供更为科学的理论依据。着重综述PK/PD模型的发展和在临床前和临床中的应用,证实了PK/PD模型可以为新药评价提供有效的理论指导,并大幅度缩短实验周期,节省实验资源,比传统的药物开发策略更加准确可靠。随着药物评价学的不断完善,模拟软件和模拟条件的标准化,PK/PD模型在未来的药物开发中必将更充分地发挥其重要作用并加速药物开发的进程。

引用

页码：161 / 166

页数：6

共 21 条

[1]

PK/PD: new insights for antibacterial and antiviral applications [J].

Schmidt, Stephan ;

Barbour, April ;

Sahre, Martina ;

Rand, Kenneth H. ;

Derendorf, Hartmut .

CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (05) :549-556

[2]

Single-Dose Pharmacokinetics and Pharmacodynamics of RWJ 67657; a Specific p38 Mitogen-Activated Protein Kinase Inhibitor: A First-in-Human Study.[J].Dolly A. Parasrampuria;Peter de Boer;Daksha Desai-Krieger;Andrew T. Chow;C. Richard Jones.The Journal of Clinical Pharmacology.2003, 4

[3]

Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women [J].

Nagaraja, NV ;

Pechstein, B ;

Erb, K ;

Klipping, C ;

Hermann, R ;

Locher, M ;

Derendorf, H .

JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (03) :243-251

[4]

How predictive is PK/PD for antibacterial agents? [J].

Frimodt-Moller, N .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) :333-339

[5]

Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networks [J].

Haidar, SH ;

Johnson, SB ;

Fossler, MJ ;

Hussain, AS .

PHARMACEUTICAL RESEARCH, 2002, 19 (01) :87-91

[6]

Pharmacokinetics and its role in small molecule drug discovery research [J].

Jang, GR ;

Harris, RZ ;

Lau, DT .

MEDICINAL RESEARCH REVIEWS, 2001, 21 (05) :382-396

[7]

Pharmacokinetic/Pharmacodynamic Modeling in Drug Development.[J].L. B. Sheiner;J.-L. Steimer.Annual Review of Pharmacology and Toxicology.2000, 1

[8]

Carbamazepine pharmacokinetics–pharmacodynamics in genetically epilepsy-prone rats.[J].James F Graumlich;Richard G McLaughlin;Donna Birkhahn;Neha Shah;Annette Burk;Phillip C Jobe;John W Dailey.European Journal of Pharmacology.1999, 3

[9]

Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives [J].

Derendorf, H ;

Meibohm, B .

PHARMACEUTICAL RESEARCH, 1999, 16 (02) :176-185

[10]

Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines I: Lorazepam.[J].Samir K. Gupta;Everett H. Ellinwood;Arlene M. Nikaido;Douglas G. Heatherly.Journal of Pharmacokinetics and Biopharmaceutics.1990, 2

← 1 2 3 →